These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32474514)

  • 41. Single-Institution Experience with Irreversible Electroporation for T4 Pancreatic Cancer: First 50 Patients.
    Kluger MD; Epelboym I; Schrope BA; Mahendraraj K; Hecht EM; Susman J; Weintraub JL; Chabot JA
    Ann Surg Oncol; 2016 May; 23(5):1736-43. PubMed ID: 26714959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. The use of IRE in multi-modality treatment for oligometastatic pancreatic cancer.
    Hong Y; Rice J; Sharma D; Martin RCG
    Am J Surg; 2018 Jul; 216(1):106-110. PubMed ID: 29506753
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Irreversible electroporation therapy in the management of locally advanced pancreatic adenocarcinoma.
    Martin RC; McFarland K; Ellis S; Velanovich V
    J Am Coll Surg; 2012 Sep; 215(3):361-9. PubMed ID: 22726894
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Evaluating the Regulatory Immunomodulation Effect of Irreversible Electroporation (IRE) in Pancreatic Adenocarcinoma.
    Pandit H; Hong YK; Li Y; Rostas J; Pulliam Z; Li SP; Martin RCG
    Ann Surg Oncol; 2019 Mar; 26(3):800-806. PubMed ID: 30610562
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Early nontumorous CT findings after irreversible electroporation of locally advanced pancreatic cancer.
    Schulz B; Ou J; Van Meter T; Martin RC
    Abdom Radiol (NY); 2016 Nov; 41(11):2142-2149. PubMed ID: 27351439
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Gemcitabine plus concurrent irreversible electroporation
    Ma YY; Leng Y; Xing YL; Li HM; Chen JB; Niu LZ
    World J Clin Cases; 2020 Nov; 8(22):5564-5575. PubMed ID: 33344547
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Irreversible Electroporation in Locally Advanced Pancreatic Adenocarcinoma: Aiming to Improve Overall Survival.
    Enjuto DT; Herrera Merino N; Abadal Villandrade JM; Gálvez González E; Llorente Lázaro R; Díaz Peña P; Álvarez Pérez MJ; Pérez González M
    J Gastrointest Cancer; 2020 Sep; 51(3):1084-1087. PubMed ID: 32472338
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Open irreversible electroporation for isolated local recurrence of pancreatic ductal adenocarcinoma after primary surgery.
    Heger U; Mack C; Tjaden C; Pan F; Pausch T; Hinz U; Sommer CM; Hackert T
    Pancreatology; 2021 Oct; 21(7):1349-1355. PubMed ID: 34404600
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Optimizing Patient Selection for Irreversible Electroporation of Locally Advanced Pancreatic Cancer: Analyses of Survival.
    Woeste MR; Wilson KD; Kruse EJ; Weiss MJ; Christein JD; White RR; Martin RCG
    Front Oncol; 2021; 11():817220. PubMed ID: 35096621
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Irreversible Electroporation for Nonthermal Tumor Ablation in Patients with Locally Advanced Pancreatic Cancer: Initial Clinical Experience in Japan.
    Sugimoto K; Moriyasu F; Tsuchiya T; Nagakawa Y; Hosokawa Y; Saito K; Tsuchida A; Itoi T
    Intern Med; 2018 Nov; 57(22):3225-3231. PubMed ID: 29984761
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Percutaneous irreversible electroporation for downstaging and control of unresectable pancreatic adenocarcinoma.
    Narayanan G; Hosein PJ; Arora G; Barbery KJ; Froud T; Livingstone AS; Franceschi D; Rocha Lima CM; Yrizarry J
    J Vasc Interv Radiol; 2012 Dec; 23(12):1613-21. PubMed ID: 23177107
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Safety of Irreversible Electroporation Ablation of the Pancreas.
    Lee EW; Shahrouki P; Peterson S; Tafti BA; Ding PX; Kee ST
    Pancreas; 2021 Oct; 50(9):1281-1286. PubMed ID: 34860812
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Efficacy of preoperative immunonutrition in locally advanced pancreatic cancer undergoing irreversible electroporation (IRE).
    Martin RC; Agle S; Schlegel M; Hayat T; Scoggins CR; McMasters KM; Philips P
    Eur J Surg Oncol; 2017 Apr; 43(4):772-779. PubMed ID: 28162818
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Sequential Irreversible Electroporation for Locally Advanced Pancreatic Cancer.
    Ong DY; Pua U
    Diagnostics (Basel); 2023 Nov; 13(22):. PubMed ID: 37998594
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The role of irreversible electroporation (IRE) for locally advanced pancreatic cancer: a systematic review of safety and efficacy.
    Ansari D; Kristoffersson S; Andersson R; Bergenfeldt M
    Scand J Gastroenterol; 2017 Nov; 52(11):1165-1171. PubMed ID: 28687047
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Concurrent chemotherapy alone versus irreversible electroporation followed by chemotherapy on survival in patients with locally advanced pancreatic cancer.
    Belfiore G; Belfiore MP; Reginelli A; Capasso R; Romano F; Ianniello GP; Cappabianca S; Brunese L
    Med Oncol; 2017 Mar; 34(3):38. PubMed ID: 28161827
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Management of borderline and locally advanced pancreatic cancer: where do we stand?
    He J; Page AJ; Weiss M; Wolfgang CL; Herman JM; Pawlik TM
    World J Gastroenterol; 2014 Mar; 20(9):2255-66. PubMed ID: 24605025
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The Value of CA19-9 After Irreversible Electroporation for Pancreatic Cancer.
    Månsson C; Nilsson A; Urdzik J; Karlson BM
    Anticancer Res; 2019 Nov; 39(11):6193-6196. PubMed ID: 31704847
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A retrospective study of CT-guided percutaneous irreversible electroporation (IRE) ablation: clinical efficacy and safety.
    Wang Z; Lu J; Huang W; Wu Z; Gong J; Wang Q; Liu Q; Wang C; Zhu Y; Ding X; Wang Z
    BMC Cancer; 2021 Feb; 21(1):124. PubMed ID: 33546635
    [TBL] [Abstract][Full Text] [Related]  

  • 60. [Irreversible electroporation in the treatment of locally advanced pancreatic cancer].
    Záruba P; Hoskovec D; Lacman J; Hořejš J; Krška Z; Ryska M
    Rozhl Chir; 2015 Dec; 94(12):504-9. PubMed ID: 26767900
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.